Amylyx Pharmaceuticals, Inc. (AMLX) vs Indivior Pharmaceuticals Inc. (INDV)
- Amylyx Pharmaceuticals, Inc. AMLX 26.34 −4.74%
- Indivior Pharmaceuticals Inc. INDV 32.45 −3.48%
Amylyx Pharmaceuticals, Inc. and Indivior Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Indivior Pharmaceuticals Inc. is the larger, with a market value of $4.0B against $3.5B — 1.1× the size. Amylyx Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Indivior Pharmaceuticals Inc. trades at 11.2×. Indivior Pharmaceuticals Inc. grew revenue faster over the last twelve months: 13.5% against −77.1%. Indivior Pharmaceuticals Inc. has the higher net margin (26.8% vs 0.00%) and the higher return on invested capital (460.5% vs 0.00%). Across the 16 metrics below, Indivior Pharmaceuticals Inc. leads on 13 and Amylyx Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | AMLX | INDV | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | 81.97% | 53.94% |
| Operating margin | 0.00% | 31.56% | 0.00% |
| Net margin | 0.00% | 26.75% | 0.00% |
| Free cash flow margin | 0.00% | (8.34%) | 0.00% |
| Return on equity | (74.73%) | (153.12%) | (0.40%) |
| Return on assets | (66.25%) | 26.52% | (3.32%) |
| Return on invested capital | 0.00% | 460.53% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack